Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,473.60 -4.30 (-0.08%) Dow
39,107.49 -20.31 (-0.05%) Nasdaq
17,835.81 +30.66 (+0.17%) Bitcoin USD
61,782.22 +719.45 (+1.18%) CMC Crypto 200
1,288.01 +21.86 (+1.73%)
Sanofi (SANP.XC)
| Previous close | 91.03 |
| Open | 89.74 |
| Bid | 89.65 x 0 |
| Ask | 90.15 x 0 |
| Day's range | 89.74 - 90.15 |
| 52-week range | 80.89 - 104.24 |
| Volume | |
| Avg. volume | 1,122 |
| Market cap | 112.787B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 24.97 |
| EPS (TTM) | 3.61 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 3.76 (4.13%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
GlobeNewswireDupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent
GlobeNewswirePress Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has published results from a positive pha
- GlobeNewswire
Press Release: Availability of the Q2 2024 Aide-mémoire
Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q2-results-2024 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well
